Clinical Trials
159 trialsONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
ASPEN-09-03
ALX Oncology Inc.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
OMNIRAY
Eli Lilly and Company
HERMIA
Abscint NV/SA
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shenzhen Ionova Life Sciences Co., Ltd.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
NeoB-Cap1
Novartis
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Ottawa Hospital Research Institute
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
OP-NEU-101
Onchilles Pharma Inc
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
National Cancer Institute (NCI)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
HER2 CR
Nagoya City University
TB06
AstraZeneca
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Vanderbilt-Ingram Cancer Center
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
ESTHER
Dartmouth-Hitchcock Medical Center
REFLECT
University Health Network, Toronto
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Harvesting Cells for Experimental Cancer Treatments
National Institutes of Health Clinical Center (CC)
ASSET
University of Kansas Medical Center
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
ASSIST
Massachusetts General Hospital
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
PROBE-CTC
ScreenCell
CER
Cancer Support Community, Research and Training Institute, Philadelphia
ToPCourT
Wake Forest University Health Sciences
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer
University of Maryland, Baltimore
SERENA-6
AstraZeneca
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.